The FDA is doubling down on its goal to increase biosimilar drug availability in the U.S. with a fresh draft guidance proposing more changes to streamline development of the cheaper biologic copies.
The FDA has issued updated guidance that aims to make it easier for drugmakers to bring biosimilars of patent-expired biologic drugs to market, in the hope of reducing medicine prices. In a pair of ...
DUBLIN--(BUSINESS WIRE)--The "Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, and Large Molecule), By Test Type (ADME, PK, PD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results